GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (NAS:AVEO) » Definitions » ROC (Joel Greenblatt) %

AVEO Pharmaceuticals (AVEO Pharmaceuticals) ROC (Joel Greenblatt) % : -2,990.34% (As of Sep. 2022)


View and export this data going back to 2010. Start your Free Trial

What is AVEO Pharmaceuticals ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. AVEO Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was -2,990.34%.

The historical rank and industry rank for AVEO Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:

AVEO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -107986.96   Med: -1209.43   Max: -224.69
Current: -5370.33

During the past 13 years, AVEO Pharmaceuticals's highest ROC (Joel Greenblatt) % was -224.69%. The lowest was -107986.96%. And the median was -1209.43%.

AVEO's ROC (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -339.53 vs AVEO: -5370.33

AVEO Pharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


AVEO Pharmaceuticals ROC (Joel Greenblatt) % Historical Data

The historical data trend for AVEO Pharmaceuticals's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals ROC (Joel Greenblatt) % Chart

AVEO Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -2,727.05 -5,799.65

AVEO Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,010.88 -3,737.83 -8,551.36 -8,038.20 -2,990.34

Competitive Comparison of AVEO Pharmaceuticals's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, AVEO Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVEO Pharmaceuticals's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AVEO Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where AVEO Pharmaceuticals's ROC (Joel Greenblatt) % falls into.



AVEO Pharmaceuticals ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(15.279 + 1.32 + 2.979) - (22.073 + 0 + 4.237)
=-6.732

Working Capital(Q: Sep. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(18.717 + 1.106 + 2.463) - (25.2 + 0 + 5.728)
=-8.642

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of AVEO Pharmaceuticals for the quarter that ended in Sep. 2022 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2022 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2022  Q: Sep. 2022
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-8.672/( ( (0.323 + max(-6.732, 0)) + (0.257 + max(-8.642, 0)) )/ 2 )
=-8.672/( ( 0.323 + 0.257 )/ 2 )
=-8.672/0.29
=-2,990.34 %

Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AVEO Pharmaceuticals  (NAS:AVEO) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


AVEO Pharmaceuticals ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


AVEO Pharmaceuticals (AVEO Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
30 Winter Street, Boston, MA, USA, 02108
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.
Executives
Jebediah Ledell officer: Chief Operating Officer C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Michael P Bailey director, officer: President & CEO IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Michael Ferraresso officer: Chief Commercial Officer AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Kevin Joseph Cullen director AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Epperly Corinne director AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Forest Baskett 10 percent owner
Joshua Makower 10 percent owner 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Scott D Sandell 10 percent owner
Growth Equity Opportunities Iv, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Erick Lucera officer: Chief Financial Officer 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Scarlett Spring director AVEO PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Peter J Barris 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202

AVEO Pharmaceuticals (AVEO Pharmaceuticals) Headlines

From GuruFocus